Targeting metabolic vulnerabilities in ETP-all

Early T cell precursor leukemia (ETP ALL) is an aggressive hematologic malignancy that requires treatment with intensified chemotherapy. Thus, further advances in the treatment of this disease require the development of effective and highly specific molecularly targeted anti-leukemic drugs. There is growing awareness that targeting the metabolic differences between tumor and normal cells holds promise as a novel anticancer strategy.